No Data
Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.
Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry
【Hong Kong stock connect】In the afternoon, China Ji Pharmaceutical (02171) rose more than 27%. The safety of the CT0590 universal CAR-T cell therapy is controllable.
Kingwoods Financial News | In the afternoon, Keyi Pharmaceutical (02171) expanded its increase, as of press time, up 27.27%, at 6.02 Hong Kong dollars, with a turnover of 0.155 billion Hong Kong dollars. The company recently announced that it will showcase the research data of SaikaiZe (Zuvorkeyloron Injection), CT071, and CT0590 in poster form at the 66th American Society of Hematology Annual Meeting, scheduled for December 7-10, 2024. Summaries of these products have been released on the ASH official website. Preliminary results of the CT0590 study indicate the safety of the CT0590 universal CAR-T cell therapy.
CARsgen to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress
CARsgen U.S. Clinical Holds Lifted by FDA
The clinical trial suspension of Keji Pharmaceutical in the USA has been lifted by the FDA.
Shanghai, November 1, 2024 / USA Today / - Koji Pharmaceutical (Stock Code: 2171.HK), a company mainly focused on innovative CAR-T cell therapy for treating hematologic malignancies and solid tumors, announced that the Food and Drug Administration ("FDA") of the United States has lifted the restrictions on Zevorcel Injection (zevor-cel, CT053, an autologous CAR-T cell product targeting BCMA), and Svlricel Injection (satri-cel, CT041, an autologous CAR-T cell product targeting Claudin18.2).
Kaiser Pharmaceuticals -B (02171.HK): FDA has lifted the US clinical trial suspension for Zepoviorolinsae injection, Shiruigiolinsae injection, and CT071.
The FDA has lifted the clinical trial suspension of zevor-cel (CT053, a autologous CAR-T cell product targeting BCMA), satri-cel (CT041, a autologous CAR-T cell product targeting Claudin18.2), as well as CT071 (a autologous CAR-T cell product targeting GPRC5D) by Science Pharmaceuticals-B (02171.HK) in the United States. On November 1, Grondway reported this news.
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% DropNo Data
No Data
